Form 4: Theravance Biopharma Director Receives New Equity Grants

Director Donal O'Connor was granted 6,009 ordinary shares and 13,398 stock options as part of his annual compensation package.

Summary

• Donal O'Connor, a director at Theravance Biopharma, Inc. (TBPH), received 6,009 ordinary shares on June 12, 2026.
• The shares were acquired at no cost ($0.00), representing a restricted equity award.
• O'Connor was also granted 13,398 share options with an exercise price of $16.64 per share.
• Following these transactions, O'Connor's total direct ownership in the company increased to 80,213 ordinary shares.
• The options are scheduled to vest monthly over a 12-month period or fully upon the next annual meeting.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive administrative event, showing continued commitment from board leadership through equity alignment.

Positives

• Increased insider ownership aligns the director's interests with those of the shareholders.
• The exercise price of $16.64 for the options suggests a baseline for future value creation expectations.
• The vesting schedule incentivizes continued service on the board of directors.

Negatives

• The issuance of new shares and options results in a minor dilution of existing shareholder equity.

Risks

• The stock options will only provide value to the director if the market price exceeds the $16.64 exercise price before the 2036 expiration.
• The equity value is subject to the volatile nature of the biopharmaceutical sector.

Future Outlook

The director's compensation is structured to vest over the coming year, indicating a focus on short-to-medium term board stability and alignment with share price performance.

Management Comments

• This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date.

Industry Context

StockSavvy.ai notes that equity-based compensation for directors is a standard practice in the biopharmaceutical industry to ensure board members are incentivized to drive long-term shareholder value without depleting cash reserves.

Comparison to Industry Standards

• The grant size is consistent with mid-cap biotechnology board compensation structures.
• The 10-year option term is a standard duration for incentive stock options in the NASDAQ-listed healthcare sector.

Corporate Governance

Related Party Transactions

• The grant of equity to a director is a related party transaction disclosed under SEC Section 16(a) rules.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of 6,009 shares and potential future issuance of 13,398 shares upon option exercise.

Next Steps

• Vesting of 1/12th of the options on a monthly basis.
• Full vesting of any remaining unvested shares on the date of the next annual meeting of shareholders.

Key Dates

Recommendation

This is a routine insider filing for director compensation and does not signal a change in company fundamentals or immediate price movement.

Keywords

Theravance Biopharma, TBPH, Insider Trading, Form 4, Director Compensation, Stock Options, Equity Grant